Made at the 4th Global Precision Medicine and Biomarkers Leader Summit: Europe by Thierry Wurch. For more information visit http://www.global-engage.com/wp-content/uploads/2017/04/Global-Precision-Medicine-Biomarkers-Europe-2017.pdf. During the last decade, breakthrough therapies in Oncology emerged such as bi-specific antibody-like molecules engaging T cells and patients-derived T cells, engineered to express a chimeric antigen receptor (CAR) to trigger T cell activation upon binding to a tumor antigen. • These two therapeutic approaches engaging effector T lymphocytes will be discussed through case studies of molecules from our immunotherapy pipeline in partnership with US and European Biotechs.

11. A word on synovial biopsies
Blood-based testing seems diicult.
Confidential document, property of DNAlytics, not to be further distributed Document date: 18/09/2017

12. A word on synovial biopsies
Synovial tissue biopsies ...

… are core topic for many KOLs : PEAC, STRAP, R4RA, ...

… seem now well accepted :

EULAR and ACR put in place massive trainings

Easy and fast (~20min)

Agreeableness of the patient.
Confidential document, property of DNAlytics, not to be further distributed Document date: 18/09/2017

13. A word on synovial biopsies
Our synovial biopsies transportation kits :

Are CE-marked

Are UN3373 (validated for air transportation)

Have been tested for temperature and duration deviations

Are used with satisfaction in routine
Confidential document, property of DNAlytics, not to be further distributed Document date: 18/09/2017

14. RheumaKit-Timeline
Confidential document, property of DNAlytics, not to be further distributed Document date: 18/09/2017

15. RheumaKit-Timeline

Security :

OWASP2013-Top10 compliant

Secured connections (https)

Privacy :

Doctors remain owner of submited data

Compliant with european directive (and will adapt to GDPR in 2018)

Software included in CE-marking dossier

Visibility :

4 Languages (EN, FR, NL, DE)

More than 4000 visits monthly

About 400 registered professionnal users
Confidential document, property of DNAlytics, not to be further distributed Document date: 18/09/2017

18. PAnTheRA: Toward RheumaKit-Tx

Predictive Analytics for Theranosis in RA. Multicentric, international.

Recruit 110 RA patients non-responding to MTX and eligible to anti-TNFs

For operations, mimics the future routine use (biopsy, transportation, lab, …)

Interim analysis 1st half 2018 should allow to have RheumaKit-Tx on the
market : pathway and drug target analysis calibrated on RA non-responding to
synthetic therapies DMARD prioritisation.⇒

Final analysis should allow for real treatment response prediction
Confidential document, property of DNAlytics, not to be further distributed Document date: 18/09/2017

19. Opportunities for collaboration
You are …
… a clinical dept. of rheumatology ?
⇒ Implement RheumaKit in your institution
⇒ Join or clinical study
… a public or private health insurer ?
⇒ Earn money by reimbursing/funding our solution for your patients
… a DMARD developer/manufacturer ?
⇒ Enhance your drug positioning by collaborating with us
… responsible for R&D in industry or academia ?
⇒ Beneit from our data mining expertise.
Confidential document, property of DNAlytics, not to be further distributed Document date: 18/09/2017